Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 25th, 2026

Beaconlight Capital LLC increased its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 44.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 33,589 shares of the medical research company’s stock after buying an additional 10,303 shares during the quarter. Natera accounts for about 3.6% of Beaconlight Capital LLC’s holdings, making the stock its 9th biggest holding. Beaconlight Capital LLC’s holdings in Natera were worth $6,717,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Integrated Wealth Concepts LLC increased its position in Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares in the last quarter. NewEdge Advisors LLC grew its stake in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares during the last quarter. Focus Partners Wealth increased its holdings in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after buying an additional 474 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of Natera in the 2nd quarter valued at $298,000. Finally, WINTON GROUP Ltd bought a new position in shares of Natera in the 2nd quarter valued at $558,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling In related news, Director Herm Rosenman sold 16,530 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the transaction, the director owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. This trade represents a 79.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $272.90, for a total value of $818,700.00. Following the transaction, the insider directly owned 134,643 shares in the company, valued at approximately $36,744,074.70. The trade was a 2.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 178,872 shares of company stock worth $39,627,696 over the last ninety days. Insiders own 5.05% of the company’s stock.

Natera Trading Down 1.0% Shares of NTRA stock opened at $261.99 on Friday. The firm has a fifty day simple moving average of $240.75 and a two-hundred day simple moving average of $221.61. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04. The firm has a market capitalization of $37.52 billion, a PE ratio of -160.73 and a beta of 1.51.

Wall Street Analysts Forecast Growth Several equities research analysts recently weighed in on the company. Guggenheim raised their price objective on Natera from $270.00 to $290.00 and gave the company a “buy” rating in a report on Monday, June 29th. TD Cowen reiterated a “buy” rating on shares of Natera in a research report on Wednesday, July 15th. Morgan Stanley lifted their price target on Natera from $250.00 to $310.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Sanford C. Bernstein started coverage on Natera in a report on Friday, June 26th. They set an “outperform” rating and a $310.00 price target on the stock. Finally, UBS Group set a $260.00 price objective on Natera in a research note on Wednesday, June 24th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $267.83.

Read Our Latest Research Report on Natera

About Natera (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Recommended Stories Five stocks we like better than Natera AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Plugging In: How Kinder Morgan Powers Up Profits Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAristotle Capital Management LLC Lowers Position in Blackstone Inc. $BX

NEXT HEADLINE »Bank of Nova Scotia Raises Holdings in Deere & Company $DE

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System lessened its stake in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 23.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171,151 shares of the medical research company’s stock after selling 52,312 shares during the quarter. California Public Employees Retirement System owned about 0.12% of Natera worth $34,228,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Horizon Investments LLC increased its stake in Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after buying an additional 44 shares during the period. Sound Income Strategies LLC lifted its stake in shares of Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after acquiring an additional 45 shares during the period. Savvy Advisors Inc. boosted its holdings in shares of Natera by 3.1% in the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after acquiring an additional 46 shares in the last quarter. First Horizon Corp boosted its holdings in shares of Natera by 5.5% in the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 51 shares in the last quarter. Finally, Siemens Fonds Invest GmbH increased its stake in shares of Natera by 3.1% during the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after acquiring an additional 54 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Up 1.7% Shares of NTRA opened at $267.18 on Wednesday. The company has a 50-day simple moving average of $236.50 and a 200-day simple moving average of $220.83. The company has a market capitalization of $38.26 billion, a PE ratio of -163.91 and a beta of 1.51. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $288.04.

Wall Street Analyst Weigh In NTRA has been the subject of several analyst reports. Canaccord Genuity Group increased their price target on shares of Natera from $285.00 to $330.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Piper Sandler reiterated an “overweight” rating and set a $249.00 target price on shares of Natera in a research report on Tuesday, May 12th. UBS Group set a $260.00 target price on Natera in a research note on Wednesday, June 24th. Finally, Wolfe Research started coverage on Natera in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $267.83.

Check Out Our Latest Analysis on NTRA

Insider Activity In other news, insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $272.90, for a total transaction of $818,700.00. Following the sale, the insider owned 134,643 shares of the company’s stock, valued at $36,744,074.70. The trade was a 2.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer owned 108,743 shares in the company, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,872 shares of company stock valued at $39,627,696 in the last quarter. Insiders own 5.05% of the company’s stock.

About Natera (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Featured Stories Five stocks we like better than Natera Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAlesco Advisors LLC An ESL Co Invests $912,000 in BlackRock $BLK

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. reduced its position in Natera, Inc. (NASDAQ:NTRA – Free Report) by 10.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 423,424 shares of the medical research company’s stock after selling 47,660 shares during the quarter. Natera makes up 1.2% of Amova Asset Management Americas Inc.’s portfolio, making the stock its 29th largest holding. Amova Asset Management Americas Inc. owned approximately 0.30% of Natera worth $84,685,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Robinhood Asset Management LLC bought a new position in Natera in the fourth quarter valued at $12,981,000. Systrade AG acquired a new stake in Natera in the 4th quarter valued at $11,454,000. J. Safra Sarasin Holding AG bought a new stake in Natera during the 4th quarter worth about $2,825,000. UBS Group AG boosted its stake in shares of Natera by 19.4% during the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock worth $100,538,000 after buying an additional 71,355 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of Natera by 25.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 45,835 shares of the medical research company’s stock worth $11,476,000 after buying an additional 9,424 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades A number of research firms recently issued reports on NTRA. Barclays lowered their target price on Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 24th. Guggenheim raised their price target on Natera from $270.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Evercore reaffirmed an “outperform” rating and set a $300.00 price target on shares of Natera in a research report on Monday, July 6th. Piper Sandler reiterated an “overweight” rating and set a $249.00 price objective on shares of Natera in a research note on Tuesday, May 12th. Finally, Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $267.83.

Check Out Our Latest Stock Analysis on Natera

Natera Stock Performance NASDAQ:NTRA opened at $262.63 on Tuesday. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04. The firm’s 50-day simple moving average is $235.24 and its 200 day simple moving average is $220.56. The firm has a market cap of $37.61 billion, a price-to-earnings ratio of -161.12 and a beta of 1.51.

Insider Activity at Natera In related news, Director Roelof Botha sold 78,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the sale, the director owned 1,076,198 shares of the company’s stock, valued at $237,097,181.38. This represents a 6.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,405 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $203.69, for a total value of $693,564.45. Following the transaction, the insider owned 142,295 shares in the company, valued at approximately $28,984,068.55. This trade represents a 2.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 178,872 shares of company stock valued at $39,627,696. 5.05% of the stock is currently owned by company insiders.

Natera Company Profile (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Read More Five stocks we like better than Natera The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAlTi Global Inc. Makes New Investment in Church & Dwight Co., Inc. $CHD

NEXT HEADLINE »Amova Asset Management Americas Inc. Has $87 Million Stake in CoreWeave Inc. $CRWV

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically includes:Kidney: 6 tests in year 1; 4 per year in years 2-3. “For-cause” coverage remai.

Key Takeaways Natera's Signatera earned EU IVDR certification across multiple types of cancer and care settings.The certification covers the assay, specimen kit and software after a comprehensive review.NTRA gained 2.7% yesterday as the approval supported Signatera's commercial expansion in Europe. Natera (NTRA - Free Report) announced that its molecular residual disease (MRD) test, Signatera, received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR) for use across multiple types of cancer. Signatera is certified to be used in adjuvant and surveillance settings across a broad range of cancers, including gastrointestinal, genitourinary, breast, skin, gynecological, head and neck, non-small cell lung cancer, and diffuse large B-cell lymphoma, indolent non-Hodgkin's lymphomas and pan-cancer immunotherapy monitoring.

The certification makes Signatera the first personalized MRD test for solid tumors to achieve IVDR certification in the European Union.

Per management, achieving the IVDR certification reaches a milestone in Natera's strategy to expand Signatera MRD testing across Europe. Supported by extensive clinical evidence across multiple cancer types, the certification builds on the company's recent regulatory successes in the United States and Japan.

Likely Trend of NTRA Stock Following the NewsFollowing the announcement, Natera’s shares gained 2.7% at yesterday’s closing. Year to date, the NTRA stock has risen 23% against the industry’s 0.1% decline. The S&P 500 has returned 10.3% in the same timeframe.

The IVDR certification is likely to strengthen investor sentiment by supporting Signatera’s commercial expansion across European markets. The approval reduces regulatory hurdles for future clinical trial launches and allows Natera to continue offering the test beyond the European Union’s IVDD transition deadline in 2028. As adoption of MRD-diagnosed cancer management continues to grow, the latest certification may further enhance Natera’s competitive position in the evolving precision oncology diagnostics market.

NTRA currently has a market capitalization of $39.30 billion.

Image Source: Zacks Investment Research

More on the NewsThe IVDR certification is regarded as one of the world's most stringent regulatory frameworks for in vitro diagnostic medical devices. The certification covers the entire Signatera platform, including the assay, specimen collection kit and associated software, following a comprehensive review of its analytical validity, clinical performance and quality management systems.

The latest achievement builds on Natera’s two major regulatory achievements for Signatera in recent months. In June 2026, Signatera received approval from Japan’s Pharmaceuticals and Medical Devices Agency for colorectal cancer patients, while in May 2026, the FDA approved Signatera CDx as a companion diagnostic for patients with muscle-invasive bladder cancer. Together, these milestones strengthen Natera’s global presence and position the company to drive broader adoption of personalized MRD testing across international markets.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the minimal residual disease testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.

Factors such as the demand for highly sensitive technologies like next-generation sequencing and digital PCR, which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.

Other NewsNatera recently partnered with Aveta Biomics to support AVTA 30-01, a global Phase 3 registrational trial of its oral immunotherapy, APG-157, in patients with locally advanced head and neck squamous cell carcinoma. Natera’s Signatera test will be integrated into the AVTA 30-01 Phase 3 study to assess MRD and treatment response during neoadjuvant, induction, adjuvant and follow-up care.

Natera partnered with Eledon Pharmaceuticals to integrate its Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed to prevent organ rejection in kidney transplantation.

Natera announced a collaboration with CytoDyn to evaluate ctDNA dynamics and generate real-world molecular data in support of the latter’s metastatic colorectal cancer program.

NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , West Pharmaceutical (WST - Free Report) and Pacific Biosciences of California (PACB - Free Report) .

Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 adjusted earnings of 52 cents per share, which beat the Zacks Consensus Estimate by 52.9%. Revenues of $139.1 million surpassed the Zacks Consensus Estimate by 6.6%. You can see the complete list of today’s Zacks #1 Rankstocks here.

Veracyte has an estimated earnings growth rate of 5.1% for 2026. VCYT’s earnings surpassed estimates in the trailing four quarters, the average surprise being 45.9%.

West Pharmaceutical, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 earnings per share of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.

Pacific Biosciences, carrying a Zacks Rank #2 at present, reported a first-quarter 2026 adjusted loss per share of 12 cents, which was narrower than the Zacks Consensus Estimate by 29.4%. Revenues of $37.2 million missed the Zacks Consensus Estimate by 9.3%.

Pacific Biosciences has an estimated earnings growth rate of 22.6% for 2026. PACB’s earnings surpassed estimates in the trailing four quarters, the average surprise being 29.8%.

-

Signatera is the first personalized molecular residual disease (MRD) test for solid tumors to receive IVDR certification in the EU

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR).

The IVDR represents one of the world’s most rigorous regulatory frameworks for in vitro diagnostic medical devices, replacing the outgoing In Vitro Diagnostic Medical Devices Directive (IVDD). To obtain certification, the Signatera platform — including the assay, specimen collection kit, and associated software — underwent a comprehensive review against some of the most stringent standards in the medical industry, including evidence of analytical and clinical validity, as well as quality system management.

IVDR certification reduces the lead time and regulatory overhead for launching new clinical trials, and it ensures that Natera can continue offering Signatera to EU patients after the IVDD transition deadline in 2028.

Under this certification, Signatera is indicated for use in the adjuvant and surveillance settings across gastrointestinal malignancies, genitourinary malignancies, non-small cell lung cancer, head and neck cancer, breast cancer, skin cancer, gynecological malignancies, diffuse large B-cell lymphoma, indolent non-Hodgkin's lymphomas, and pan-cancer immunotherapy monitoring.

Certification was supported by extensive clinical and analytical evidence demonstrating Signatera’s performance across multiple tumor types and clinical settings. It follows two significant regulatory milestones for the Signatera portfolio: in June 2026, Signatera received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for patients with colorectal cancer; and in May 2026, the U.S. Food and Drug Administration approved Signatera™ CDx as a companion diagnostic for patients with muscle-invasive bladder cancer.

“MRD testing is redefining how we assess recurrence risk and guide treatment decisions for patients with cancer,” said Julien Taieb, M.D., Ph.D., head of the gastroenterology and gastrointestinal oncology department at the Université Paris-Cité. “This certification for Signatera is an important milestone as it will enhance access to personalized MRD testing for patients across Europe within a more rigorous regulatory framework.”

“Achieving IVDR certification is a key milestone in Natera’s plan to bring Signatera MRD testing to Europe,” said Solomon Moshkevich, president, clinical diagnostics at Natera. “Backed by extensive clinical evidence across multiple cancer types, this builds on our recent regulatory approvals in both the United States and Japan.”

About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

More News From Natera, Inc.

Back to Newsroom

Key Takeaways Natera partnered with Aveta to integrate Signatera into a global Phase 3 LA-HNSCC trial.Signatera will assess MRD and treatment response across neoadjuvant to follow-up care.The trial may enroll 826 patients globally, with enrollment expected in the second half of 2026. Natera (NTRA - Free Report) recently announced a partnership with Aveta Biomics to support AVTA 30-01, a global Phase 3 registrational trial of its oral immunotherapy, APG-157, in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Natera’s Signatera test will be integrated into the AVTA 30-01 Phase 3 study to assess molecular residual disease (MRD) and treatment response during neoadjuvant, induction, adjuvant and follow-up care.

Management noted that growing clinical evidence continues to demonstrate the value of Signatera for MRD detection in head and neck cancer. The company believes its collaboration with Aveta on the AVTA 30-01 trial will further demonstrate Signatera’s potential to advance the field and improve patient care.

Likely Trend of NTRA Stock Following the NewsShares of NTRA have lost 0.3% since the announcement on Monday. Year to date, the stock has gained 18.5% against the industry’s 2.3% decline. The S&P 500 has risen 9.7% in the same timeframe.

The partnership with Aveta Biomics is a positive development for Natera as it expands the clinical use of Signatera in a global Phase 3 registrational trial. Successful validation of Signatera for MRD monitoring and treatment response in head and neck cancer could strengthen its clinical evidence and support wider adoption. Over time, the collaboration could enhance Natera’s position in precision oncology while creating opportunities for biopharma partnerships centered on MRD-guided treatment strategies.

NTRA currently has a market capitalization of $39.00 billion.

Image Source: Zacks Investment Research

More on the NewsAPG-157 is Aveta’s first-in-class oral immunotherapy designed to benefit both immune-hot and immune-cold tumors in LA-HNSCC. The therapy has received FDA Fast Track and Orphan Drug Designations for this indication. The Phase 3 study builds on Phase 2 results that demonstrated favorable safety, evidence of tumor control, deep molecular responses and promising event-free survival outcomes.

The trial is expected to enroll approximately 826 patients across North America, Europe, Asia-Pacific and Australia, with patient enrollment to begin in the second half of 2026. It will include separate randomized cohorts for patients with resectable and unresectable locally advanced disease, with both treatment and control arms. Signatera will serve as a secondary endpoint to generate insights into disease recurrence and therapeutic response through circulating tumor DNA (ctDNA) monitoring to assess MRD.

Head and neck cancer affects roughly 950,000 people worldwide each year, and recurrence remains a significant cause of mortality despite advances in surgery, radiation and immunotherapy. This collaboration further expands Natera’s clinical evidence in head and neck cancer, following the positive results from the recently concluded Phase 2 SINERGY trial, which supported the use of Signatera MRD-guided monitoring in this disease setting.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the minimal residual disease testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.

Factors like the demand for highly sensitive technologies like next-generation sequencing and digital PCR, which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.

Other NewsNatera recently announced a collaboration with CytoDyn to evaluate ctDNA dynamics and generate real-world molecular data in support of the latter’s metastatic colorectal cancer (mCRC) program.

In May, Natera announced a collaboration with Diakonos Oncology to incorporate its Signatera molecular residual disease test into Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial for patients with refractory melanoma.

Natera received the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab immunotherapy in patients with muscle-invasive bladder cancer.

NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .

BrightSpring Health, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.

Globus Medical, currently carrying a Zacks Rank #2, reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.

-

Signatera™ will be used to evaluate molecular response to APG-157 in the neoadjuvant, induction, and adjuvant settings

AUSTIN, Texas & BEDFORD, Mass.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors, today announced a strategic partnership supporting AVTA 30-01, Aveta’s global Phase 3 registrational clinical trial evaluating APG-157 in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (NCT07667296).

APG-157 is Aveta's first-in-class oral immunotherapy intended to expand the benefits of immunotherapy to both immune-cold and immune-hot tumors in patients with LA-HNSCC. APG-157 has received FDA Fast Track and Orphan Drug Designations for this indication.

AVTA 30-01 builds upon previously reported Phase 2 clinical data of APG-157 monotherapy in demonstrating favorable safety, evidence of tumor-control, deep molecular responses, and encouraging event-free survival outcomes. The trial will incorporate serial Signatera testing to assess molecular residual disease (MRD) and treatment response throughout therapy and follow-up. Circulating tumor DNA (ctDNA) has emerged as one of the most promising approaches for detecting MRD and identifying recurrence earlier than conventional imaging alone.

Approximately 826 patients are expected to be enrolled across North America, Europe, Asia-Pacific, and Australia. The study includes separate randomized cohorts for resectable and unresectable locally advanced disease, each with treatment and control arms, and Signatera will be a secondary endpoint. The trial is expected to begin enrollment in 2H’26.

Global annual incidence of head and neck cancer is approximately 950,000,1 and disease recurrence remains a major cause of mortality despite advances in surgery, radiation therapy, and immunotherapy.

“Patients with locally advanced head and neck cancer continue to face substantial risks of recurrence despite aggressive treatment,” said Parag Mehta, Ph.D., founder and chief executive officer of Aveta Biomics. “We believe APG-157 has the potential to transform treatment by activating anti-tumor immunity in both immune-cold and immune-hot tumors. Incorporating serial Signatera testing into AVTA 30-01 will allow us to further validate the ctDNA findings observed in Phase 2 while generating molecular response data that will advance the understanding of treatment benefits for patients and strengthen the regulatory submission.”

This study adds to the evidence Natera continues to generate in head and neck cancer. The company recently announced a successful readout of the prospective Phase 2 SINERGY trial, supporting Signatera MRD-guided treatment in this histology.

“Growing evidence continues to demonstrate the value of Signatera MRD detection in head and neck cancer,” said Eric Matthews, general manager, biopharma, Natera. “We’re pleased to partner with Aveta on AVTA 30-01 to demonstrate how Signatera has the potential to advance the field and improve care for patients.”

References

Sun H, et al. Global burden of head and neck cancer: Epidemiological transitions, inequities, and projections to 2050. Front Oncol. 2025 Sep 25;15:1665019.About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

About Aveta Biomics

Aveta Biomics is a clinical-stage immuno-oncology company advancing first-in-class oral therapies designed to reprogram the tumor microenvironment and expand the benefits of immunotherapy to patients with immune-cold cancers. The company’s lead candidate, APG-157, has received FDA Fast Track and Orphan Drug Designations for head and neck squamous cell carcinoma and is in a global phase 3 registrational trial. APG-157 is also being evaluated across additional oncology indications including high-grade adult glioma and oral dysplasia. For more information, visit www.avetabiomics.com.

Forward-Looking Statements (for Natera)

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our or our partners’ efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

Forward-Looking Statements (for Aveta)

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those regarding the impact of the Fast Track Designation, the progress of our clinical trials, potential regulatory approvals, the development and commercial success of our drug candidates, and our strategic goals, reflect our current expectations and involve risks and uncertainties. Actual results may differ materially due to factors such as our ability to advance drug candidates through development and regulatory approval, clinical trial outcomes, competition, and economic conditions. Words like “may,” “will,” “could,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. We caution you not to place undue reliance on these statements, which speak only as of the date they are made. As a private company, Aveta Biomics is under no obligation to publicly update or revise any forward-looking statements to reflect new information or future events, except as required by applicable law.

More News From Natera, Inc.

Back to Newsroom

Key Takeaways Natera's Signatera received PMDA approval in Japan for colorectal cancer in the adjuvant setting.Signatera is Japan's first PMDA-approved MRD test, supporting Natera's international expansion efforts.Natera plans a Japan launch by end-2026, pending final reimbursement and pricing decisions. Natera (NTRA - Free Report) recently announced that Signatera has received PMDA approval in Japan for use in colorectal cancer (CRC) patients in the adjuvant setting. The approval makes Signatera the first PMDA-approved molecular residual disease (MRD) test in Japan and represents an important milestone in the company’s international expansion efforts.

Per management, the approval of Signatera in Japan reflects the contributions of investigators and patients who helped build the clinical evidence supporting this milestone. The company is now focused on preparing for the commercial launch of Signatera for CRC and remains committed to expanding global access to Signatera across additional cancer types, with muscle-invasive bladder cancer representing its next planned submission in Japan.

Likely Trend of NTRA Stock Following the NewsFollowing the announcement, NTRA shares gained 10.7% at yesterday’s closing. Year to date, the stock has gained 13.5% against the industry’s 4.6% decline. The S&P 500 has risen 7.4% in the same timeframe.

The PMDA approval of Signatera may strengthen Natera’s position in the growing MRD diagnostics market and expand its commercial opportunities. Successful commercialization in Japan could drive broader adoption of Signatera among oncologists and healthcare providers seeking more personalized treatment approaches. Continued international expansion and additional regulatory approvals may further enhance Natera’s long-term growth prospects.

NTRA currently has a market capitalization of $33.62 billion.

Image Source: Zacks Investment Research

More on the NewsNatera plans to launch Signatera commercially in Japan by the end of 2026, pending final reimbursement and pricing decisions. The approval addresses a significant clinical need, as more than 150,000 people are diagnosed with CRC in Japan each year, making it one of the country’s most prevalent cancers. The incidence is comparable to that of the United States, underscoring the demand for more personalized tools in post-surgical cancer care.

The approval was backed by findings from the GALAXY clinical trial, part of the broader CIRCULATE-Japan initiative. Results showed that patients who were MRD-positive after surgery experienced significant benefit from adjuvant chemotherapy, while MRD-negative patients did not. The study analyzed 2,240 samples and is among the largest prospective investigations of MRD testing in resectable colorectal cancer, involving thousands of patients across more than 150 Japanese institutions.

The commercialization of Signatera will be supported by existing recommendations from the Japan Society of Clinical Oncology and the Japanese Society of Medical Oncology, both of which recognize the value of MRD testing in colorectal cancer management.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the MRD testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.

Factors like the demand for highly sensitive technologies like next-generation sequencing (NGS) and digital PCR (dPCR), which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.

Other NewsNatera recently announced a collaboration with CytoDyn to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insights to support CytoDyn’s metastatic colorectal cancer (mCRC) development program. Signatera, Natera’s personalized assay for the detection of MRD, will be used to evaluate ctDNA dynamics and molecular response patterns associated with leronlimab treatment.

In May, Natera announced a collaboration with Diakonos Oncology to incorporate its Signatera molecular residual disease test into Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial for patients with refractory melanoma.

NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .

BrightSpring Health, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank stocks here.

BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera's Prospera kidney transplant assessment test into Eledon's planned Phase 3 clinical trial of tegoprubart, an in.

The precision medicine company expects to launch Signatera commercially in Japan by the end of 2026, pending final pricing decisions.

The approval marks a key milestone in Natera’s international oncology expansion.

More than 150,000 people are diagnosed with colorectal cancer each year in Japan, making it one of the country’s most common cancers and highlighting the need for personalized treatment strategies.

Clinical Evidence And Medical Society Support Back ApprovalThe cancer test company said findings from the GALAXY clinical trial supported regulatory clearance.

The study showed that patients who tested MRD-positive following surgery experienced substantial benefit from adjuvant chemotherapy, while MRD-negative patients did not appear to benefit from the treatment.

The GALAXY trial analyzed 2,240 samples, making it one of the largest prospective studies evaluating MRD testing in resectable colorectal cancer.

The study forms part of the broader CIRCULATE-Japan platform, which involves thousands of patients and more than 150 institutions across Japan.

SRL To Lead Commercialization Efforts Across JapanCommercial rollout of Signatera in Japan will be supported by SRL Inc., Japan’s largest reference laboratory and a member of H.U. Group Holdings.

As Natera’s exclusive business partner in Japan, SRL will help expand access to personalized MRD testing through its nationwide laboratory network.

On Tuesday, the National Comprehensive Cancer Network (NCCN) recognized Natera’s Signatera technology for muscle-invasive bladder cancer.

The recognition marks the third NCCN guideline recommendation for circulating tumor DNA (ctDNA) testing, which could enhance treatment protocols for patients, reflecting positively on Natera’s market position and growth potential.

NTRA Stock Price Activity: Natera shares were up 10.29% at $258.92 at the time of publication on Wednesday, according to Benzinga Pro data.

Photo by Michael Vi via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026. The company and its collaborators will share 21 presentations, including seven oral presentations, highlighting the utility of the Prospera test to inform risk assessment and long-term graft monitoring across kidney, heart, lung, and multi-organ transplant.

Some of the most anticipated Prospera study data to be shared include:

Even when biopsy results are negative for rejection, elevated Prospera dd-cfDNA levels were strongly predictive of future adverse outcomes, including eGFR decline, DSA positivity, and graft loss. New data from the PEDAL study in 346 kidney transplant patients with non-rejection biopsy results showed that patients with positive Prospera results, which occurred in 18.2% of these cases, had significantly higher rates of adverse outcomes, including >6X the rate of graft loss. The data suggest that positive dd-cfDNA results indicate an increased risk for adverse outcomes, even when biopsy does not show rejection.Patients with persistently low Prospera dd-cfDNA levels had reliable and significantly lower adverse outcome rates, which may enable confident decisions to lower immunosuppression. In a new analysis of 989 kidney transplant recipients from the ProActive study, when a patient’s Prospera dd-cfDNA donor-fraction remained <0.5%, patients had significantly lower rates of adverse outcomes, including ~12X reduced odds of future rejection and ~5.5X reduced odds of future graft loss. These results demonstrate that low Prospera dd-cfDNA was prognostic of durable graft stability and reiterate the importance of ongoing and regular monitoring."Natera is leading the next phase of studies and evidence generation for dd-cfDNA,” said Sangeeta Bhorade, M.D., chief medical officer, organ health, Natera. “It is well established that Prospera identifies rejection, and our new data, like that from PEDAL and ProActive, are evaluating its impact on real clinical decision making for transplant patients. These data reinforce the importance of using the Prospera test regularly as a non-invasive way to monitor patients and help guide care decisions that may support longer graft life and better outcomes.”

Full list of Natera presentations at ATC:

June 20, 5:45 PM ET | Abstract #A003
Presenter: Catherine Spellicy, Ph.D.
The Edge of Detection: Defining Critical Thresholds for the Prospera Donor-Derived Cell-Free DNA Transplant Rejection Screen

June 20, 5:45 PM ET | Abstract #A363 (ProActive)
Presenter: Jonathan Bromberg, M.D., Ph.D.
Consistently Low Donor-Derived Cell-Free DNA Identifies Allograft Stability in Kidney Transplant Recipients

June 20, 5:45 PM ET | Abstract #A380
Presenter: Mita Banik, Ph.D.
A Novel Hierarchical Machine Learning Framework for Predicting Kidney Transplant Rejection Subtype

June 21, 8:30 AM ET | Abstract #254
Presenter: Ginger DeLario, Ph.D., M.T. (ASCP), CPTC
Are Transplant APPs Ready for Certification? National Findings from the American Board for Transplant Certification (ABTC)

June 21, 2:45 PM ET | Abstract #B258
Presenter: Quinn Stein, M.S., CGC
Busting the Age Myth: Clinically Significant Genetic Findings in Living Donor Candidates Are Not Limited to the Young

June 21, 2:45 PM ET | Abstract #B261
Presenter: Keysha M. López Vega, M.D.
Genetic Testing in Kidney Transplant Candidates and Recipients: Three Cases of Adenine Phosphoribosyltransferase (APRT) Deficiency Identified in Puerto Rico

June 21, 2:45 PM ET | Abstract #B266
Presenter: Maggie Westemeyer, M.S., CGC
Positive Genetic Test Results in Living Kidney Donor Candidates: Common and Broadly Distributed Across Genes

June 21, 5:00 PM ET | Abstract #490 (Oral Presentation)
Presenter: Quinn Stein, M.S., CGC
Carrier Findings Are Common and Clinically Relevant in Living Kidney Donor Candidates

June 22, 8:15 AM ET | Abstract #554 (Trifecta Heart, Oral Presentation)
Presenter: Katelynn Madill-Thomsen, Ph.D.
In heart transplants, DSA-negative and DSA-positive antibody-mediated rejection have similar molecular features, timing, dd-cfDNA and leukocyte composition

June 22, 2:45 PM ET | Abstract #C090
Presenter: Gregory Lewis, M.D.
Biopsy to Biomarker: Evolution of Post-Heart Transplant Surveillance Practices from the ProTECT Study

June 22, 2:45 PM ET | Abstract #C093 (Trifecta Heart)
Presenter: Martina Mackova, Ph.D.
Comparing Histological Acute Cellular Rejection Grade 1R with Molecular Microscope® Diagnostic System Classifiers and Donor-Derived Cell-Free DNA (dd-cfDNA) Levels

June 22, 2:45 PM ET | Abstract #C100 (Trifecta Heart)
Presenter: Patrick Gauthier, Ph.D.
Incremental Increase in Donor-Derived Cell-Free DNA (dd-cfDNA) and Risk of Molecular Rejection in Heart Transplant (HT) Recipients

June 22, 2:45 PM ET | Abstract #C157
Presenter: Meg Hager, M.S., MPH, CGC
Conversations That Lead to Action: Genetic Counselors and Living Kidney Donors

June 22, 2:45 PM ET | Abstract #C358
Presenter: Shelley Hall, M.D.
Donor-Derived Cell-Free DNA (dd-cfDNA) and Clinical Outcomes in Heart Transplant (HT) Patients (Pts) with Antibody Mediated Rejection (AMR): ProTECT Study

June 23, 2:30 PM ET | Abstract #D083 (ProActive)
Presenter: Matthew Cooper, M.D.
Association Between dd-cfDNA and Future Development of DSA or Rejection in Kidney Transplant Recipients with TCMR

June 23, 2:30 PM ET | Abstract #D120 (ProActive)
Presenter: Sanjeev Akkina, M.D.
Dd-cfDNA in Kidney Transplant Recipients (KTRs) with Cancer

June 23, 2:30 PM ET | Abstract #D266
Presenter: Justin Rosenheck, D.O.
Torque Teno Virus (TTV) Viral Load (VL) Correlates with Tacrolimus (TAC) Levels but Not Lymphocyte Subsets or Immunoglobulins After Lung Transplantation (LT)

June 23, 2:30 PM ET | Abstract # D285
Presenter: Abraham Matar, M.D.
Donor-Derived Cell-Free DNA for Detection of Rejection After Pancreas Transplantation

June 24, 9:30 AM ET | Abstract #1314 (Trifecta Heart, Oral Presentation)
Presenter: Martina Mackova, Ph.D.
In Heart Transplants Current Standard-of-Care Management of TCMR and ABMR is Often Associated with Persistence of Molecular Rejection and Elevated dd-cfDNA

June 24, 9:30 AM ET | Abstract #1316 (Trifecta Kidney, Oral Presentation)
Presenter: Philip Halloran, M.D.
Current Standard-of-Care Management of TCMR and ABMR in Kidney Transplant Patients is Associated with Persistence of Molecular Rejection and Elevated dd-cfDNA

June 24, 9:30 AM ET | Abstract #1331 (Oral Presentation)
Presenter: Gaurav Gupta, M.D.
Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR)

June 24, 9:30 AM ET | Abstract #1333 (PEDAL, Oral Presentation)
Presenter: Yasir Qazi, M.D., Ph.D., FACS
Post-Rejection Donor-Derived Cell-Free DNA and Serum Creatinine Trends in Kidney Transplant Recipients

June 24, 9:30 AM ET | Abstract #1335 (PEDAL, Oral Presentation)
Presenter: Suphamai Bunnapradist, M.D.
Donor-Derived Cell-Free DNA as a Prognostic Biomarker in Biopsy-Negative Kidney-Transplant Recipients

About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

More News From Natera, Inc.

Key Takeaways NTRA secured FDA approval for Signatera CDx with Tecentriq in muscle-invasive bladder cancer.Signatera helped identify MIBC patients benefiting from Tecentriq in the Phase III IMvigor011 trial.Natera said MRD-negative patients showed 97% two-year survival without adjuvant therapy. Natera, Inc. (NTRA - Free Report) recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in patients with muscle-invasive bladder cancer (MIBC). The approval marks the first companion diagnostic approval in the blood-based minimal residual disease (MRD) testing space and represents a major milestone in personalized oncology care.

Management stated the FDA approval was an achievement for precision oncology and personalized medicine. It supports the company’s decade-long vision for Signatera and strengthens its position as a standard-of-care MRD solution in muscle-invasive bladder cancer. Natera’s expanding portfolio of TOMR trials and innovations in genome-based MRD and phased variant technologies aims at advancing cancer diagnostics across all cancer types.

Likely Trend of NTRA Stock Following the NewsShares of NTRA have lost 5.4% since the announcement on Friday. In the year-to-date period, shares of the company have fallen 14.7% compared with the industry’s 11.9% decline. However, the S&P 500 has risen 9% in the same timeframe.

The FDA approval of Signatera CDx as a companion diagnostic may accelerate adoption among oncologists and healthcare systems seeking personalized treatment approaches in bladder cancer care. Continued advancements in MRD-guided treatment strategies may further enhance Natera’s competitive standing in the fast-growing precision oncology and MRD diagnostics market.

NTRA currently has a market capitalization of $26.69 billion.

Image Source: Zacks Investment Research

More on the NewsThe FDA approval follows positive findings from the global Phase III IMvigor011 trial sponsored by Genentech and published in The New England Journal of Medicine in October 2025. The study demonstrated that MRD-positive MIBC patients treated with Tecentriq achieved significant improvements in disease-free survival and overall survival.

Meanwhile, MRD-negative patients achieved a 97% two-year overall survival rate without receiving adjuvant therapy, highlighting the potential of Signatera to help personalize treatment decisions while avoiding unnecessary therapy exposure.

Currently, around 30,000 new MIBC cases are diagnosed annually in the United States and nearly 150,000 worldwide. While radical cystectomy can provide long-term disease control for some patients, identifying those at high risk of recurrence has remained challenging. Findings from the IMvigor011 trial provide evidence that MRD-guided treatment using Signatera may help personalize care decisions across the bladder cancer treatment continuum.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the minimal residual disease (MRD) testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.

Factors like the demand for highly sensitive technologies like next-generation sequencing (NGS) and digital PCR (dPCR), which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.

Other NewsIn March, Natera announced the commercial launch of Zenith Genomics, a next-generation whole genome sequencing assay designed to improve the detection and diagnosis of rare genetic diseases. The core technology behind Zenith Genomics was developed by MyOme, a clinical whole genome analysis company focused on helping families better understand and assess their disease risks.

NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Globus Medical reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a significant expansion of its operations, marking a major milestone in the company's continued growth and mission to improve outcomes for patients with cancer and other serious diseases. At its North Austin headquarters campus, Natera will unveil two major expansion projects: a dedicated sequencing facility, significantly increasing capacity; and an additional s.

-

Overall program, including 3 oral presentations, delivers unmatched evidence across the MRD landscape

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place May 29–June 2 in Chicago, IL.

Together with its collaborators, Natera will demonstrate unmatched scale in evidence generation with 35 abstracts across molecular residual disease (MRD) testing and other innovations. Presentations will highlight Natera’s Treatment on MRD (TOMR) approach, showing more precise intervention upon molecular recurrence; the broad utility of Signatera as a pan-cancer foundational tool in MRD; the robust clinical performance of Natera’s ultrasensitive phased variant technology; and new real-world data on Signatera in hereditary risk assessment, treatment response monitoring, and longitudinal disease management.

“This is the most comprehensive oncology data program Natera has presented to date, reflecting the growing adoption of Signatera and the accelerating momentum behind precision MRD-guided care,” said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology. “Collectively, these studies reinforce Signatera’s broad clinical utility, highlight the continued advancement of our technology platform, and demonstrate the strength and depth of our evidence as we work to make cancer care more actionable and personalized.”

Treatment on MRD (TOMR) in Colorectal Cancer (CRC)

Multiple analyses from the GALAXY study in CRC demonstrate the value of serial Signatera testing and the potential impact of MRD-guided decision making in the adjuvant setting.

In one analysis, patients who were initially Signatera-negative but later converted to Signatera-positive derived a substantial benefit from adjuvant chemotherapy (ACT) (HR 0.3), showing Signatera can identify a subset of patients with early molecular recurrence who could benefit from ACT. Patients with sustained negativity had excellent outcomes regardless of ACT, suggesting potential overtreatment. A separate analysis showed that extending ACT beyond three months provided no added benefit for patients with sustained Signatera-negativity or Signatera clearance, whereas partial molecular responders (decrease in ctDNA) benefitted from continued ACT. Molecular progression (increase in ctDNA) on ACT indicated the need for more effective alternative treatment strategies. Pan-Cancer MRD

Natera will present a large, first-of-its-kind, real-world meta-analysis of Signatera across 18 published studies, more than 3,000 patients, and 15 tumor types. The analysis demonstrated that Signatera-positivity was strongly associated with increased risk of recurrence or disease progression at all timepoints included in the analysis.

In a pooled analysis, Signatera-positivity in the adjuvant window was associated with significantly increased risk of recurrence or death (HR: 8.15). In the surveillance setting, Signatera-positivity was associated with an even greater recurrence risk (HR: 18.30). Phased Variant Technology

Natera’s phased variant technology continues to demonstrate powerful prognostic performance across both solid and hematologic cancers. This technology, which can detect circulating tumor DNA (ctDNA) levels below 1 part per 10 million, reinforces the potential of ultra-sensitive ctDNA detection to guide treatment response monitoring and long-term disease management.

One study in early-stage, non-small cell lung cancer (NSCLC), showed that 100% of patients who cleared ctDNA during or after adjuvant therapy did not recur. ctDNA detection also preceded recurrence in 94% of cases. In a separate analysis in relapsed or refractory follicular lymphoma, patients treated with CAR T cell therapy who achieved MRD-negativity experienced substantially improved progression-free survival (PFS), including 36-month PFS rates of 81% compared to 56% in MRD-positive patients. Platform Expansion: RWD and New Digital Tools

Natera and its collaborators will present real world data evaluating ctDNA dynamics and clinical outcomes in colorectal cancer, NSCLC, breast cancer, and additional tumor types. Natera will also unveil its Annotation platform at ASCO, a new digital tool that integrates clinical, treatment, and genomic data to present multimodal, longitudinal patient journeys through a unified interface, bringing richer clinical context to Signatera results at the individual and cohort levels.

A full list of abstracts is included here.

About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

More News From Natera, Inc.

Back to Newsroom

Key Takeaways Natera is expanding its Austin headquarters, adding a dedicated sequencing facility and new operational space.NTRA said the buildout will increase lab space and sequencing to serve more patients and clinicians.Natera reported 54% YoY growth in Q1 2026 oncology testing volumes; expansion may add up to 400 jobs. Natera (NTRA - Free Report) recently announced a major expansion of its operations in Austin, TX, as part of its growth strategy and commitment to improving care for patients with cancer and other serious diseases.

Natera’s expanded facility is expected to deliver the largest sequencing capacity in the world. The expansion comes as demand for Natera’s testing solutions continues to rise, particularly in oncology. In first-quarter 2026, the company reported more than 54% year-over-year growth in oncology testing volumes.

Per management, the expansion will give Natera a greater opportunity to serve patients by increasing laboratory space and sequencing capabilities. These infrastructural investments are intended to help Natera serve more patients, support a broader network of clinicians and continue advancing personalized medicine at scale.

Likely Trend of NTRA Stock Following the NewsShares of NTRA have lost 0.2% since the announcement on Thursday. In the year-to-date period, shares of the company have fallen 11.3% compared with the industry’s 10.8% decline. However, the S&P 500 has risen 9.6% in the same timeframe.

The large-scale expansion and increased sequencing capacity may strengthen investor confidence in Natera’s long-term growth strategy. Continued momentum in oncology testing volumes, combined with broader adoption of Signatera and recent regulatory milestones, could support the company’s competitive position in the precision diagnostics market.

NTRA currently has a market capitalization of $29.10 billion.

Image Source: Zacks Investment Research

More on the NewsAt its North Austin headquarters, Natera plans to launch two expansion initiatives: a dedicated sequencing facility to substantially boost testing capacity, and an additional operational space to accommodate future business growth.

Natera’s Signatera test has become a widely adopted tool in precision oncology and is currently used by more than half of U.S. oncologists. Recently, Signatera CDx also became the first FDA-approved companion diagnostic in molecular residual disease testing.

Alongside infrastructure growth, Natera continues to invest heavily in research and development. The company is involved in hundreds of clinical studies and research partnerships to expand the role of personalized diagnostics and accelerate innovation for patients globally. The expansion is expected to create up to 400 new jobs across laboratories, and professional and operational roles.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the genetic testing market is valued at $27.32 billion in 2026 and is expected to witness a CAGR of 11.3% through 2035.

Factors like the rising prevalence of chronic diseases and technological advancements, the development of efficient and innovative genetic testing kits, and the rising awareness regarding the benefits of genetic testing among the global population are driving the market’s growth.

Other NewsNatera recently announced that enrollment in its EXPAND clinical trial has surpassed 2,000 patients, more than doubling over the past year. The study evaluates the company’s Fetal Focus single-gene noninvasive prenatal test, designed to assess fetal risk for 21 serious genetic conditions. Data presented at the 2026 SMFM Annual Meeting showed strong clinical performance. The test uses Natera’s LinkedSNP technology, which successfully identified all five challenging homozygous cases evaluated in the study.

NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .

West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.

West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.

Key Takeaways Natera upgraded Panorama NIPT, adding SNP-informed deep sequencing validated in low fetal fraction samples.In a 3,323-pregnancy study, NTRA's Panorama hit 100% sensitivity for trisomy 21/13 and 93.3% for 18.No-call rate fell to 0.5%, helping patients get results from the first blood draw, Natera said. Natera (NTRA - Free Report) recently announced a major upgrade to its Panorama non-invasive prenatal test (NIPT). Powered by the company’s novel SNP-informed deep sequencing technology, the updated Panorama NIPT is supported by clinically validated performance in samples with low fetal fraction.

According to Sheetal Parmar, SVP of Medical Affairs, Women’s Health, low fetal fraction has long been a challenge in non-invasive prenatal screening. The enhanced Panorama test combines Natera’s proprietary SNP-based technology with advanced deep sequencing capabilities to deliver strong clinical performance in low fetal fraction samples. This will help more patients obtain reliable results without increasing complexity for healthcare providers.

Likely Trend of NTRA Stock Following the NewsShares of NTRA have gained 1.1% since the announcement on Tuesday. In the year-to-date period, shares of the company have fallen 11.4% compared with the industry’s 11.6% decline. However, the S&P 500 has risen 10.3% in the same timeframe.

The launch of the enhanced Panorama NIPT may strengthen Natera’s position in the growing prenatal testing market by improving performance in a critical area of unmet need. Better clinical accuracy and lower no-call rates could support increased adoption among healthcare providers and pregnant patients. This may contribute to long-term revenue growth and strengthen Natera’s competitive standing in the precision medicine space.

NTRA currently has a market capitalization of $28.77 billion.

Image Source: Zacks Investment Research

More on the Enhanced Panorama NIPTFetal fraction is the proportion of placental DNA present in a pregnant patient’s blood sample. Low fetal fraction is associated with a higher risk of aneuploidy and has historically posed challenges for non-invasive prenatal screening methods. To address this issue, Natera developed SNP-informed deep sequencing technology to improve NIPT performance in low fetal fraction samples.

In a prospective, blinded validation study of 3,323 pregnancies, including 242 low fetal fraction samples, Panorama achieved 100% sensitivity for trisomy 21 and trisomy 13 and 93.3% for trisomy 18. The no-call rate also declined to 0.5%, allowing more patients to receive actionable results from the initial blood draw while helping Panorama address a longstanding competitive limitation.

Industry Prospects Favoring the MarketGoing by the data provided by Coherent Market Insights, the non-invasive prenatal testing market is valued at $5.62 billion in 2026 and is expected to witness a CAGR of 10.6% through 2033.

Factors like the increasing prevalence of chromosomal abnormalities among newborns and growing awareness and acceptance of non-invasive prenatal testing methods are driving the market’s growth.

Other NewsNatera recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in patients with muscle-invasive bladder cancer (MIBC). The approval marks the first companion diagnostic approval in the blood-based minimal residual disease (MRD) testing space and represents a major milestone in personalized oncology care.

NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .

West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.

West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the collaboration, Signatera will be used to longitudinally assess molecular response in patients with refractory melanoma enrolled in Diakonos' DOC-RM Phase I/II investigational immunotherapy.

Key Takeaways NTRA will deploy Signatera in Diakonos' DOC-RM Phase I/II trial for refractory melanoma.Signatera will track ctDNA over multiple timepoints as DOC1021 tests dendritic cell immunotherapy.NTRA stock rose 4.4% since Friday's news, as ctDNA monitoring may clarify response when imaging falls short. Natera (NTRA - Free Report) recently announced a collaboration with Diakonos Oncology to incorporate its Signatera molecular residual disease test into Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial for patients with refractory melanoma.

Management stated that Signatera is well suited to help biopharmaceutical companies evaluate molecular responses throughout treatment. The collaboration with Diakonos could generate deep insight into treatment response dynamics over time by tracking minimal residual disease (MRD) at multiple stages, potentially supporting the future development of treatments for difficult cancers.

Likely Trend of NTRA Stock Following the NewsShares of NTRA have gained 4.4% since the announcement on Friday. In the year-to-date period, shares of the company have fallen 2.5% compared with the industry’s 9.8% decline. However, the S&P 500 has risen 11.1% in the same timeframe.

In the long run, the collaboration strengthens Natera’s position in precision oncology and biopharma research by expanding the application of Signatera in clinical-stage immunotherapy programs. The partnership provides Natera with an opportunity to demonstrate the value of ctDNA monitoring in difficult-to-treat cancers, where traditional radiographic assessments may not fully capture treatment response. The initiative also supports Natera’s strategy of increasing adoption of Signatera across drug development programs and advancing the use of molecular diagnostics to guide personalized cancer care.

NTRA currently has a market capitalization of $31.99 billion.

Image Source: Zacks Investment Research

More on the NewsThe DOC-RM trial, which started enrolling patients in May, is evaluating DOC1021 (dubodencel), Diakonos’ personalized dendritic cell immunotherapy that received FDA Fast Track designation for unresectable or metastatic cutaneous melanoma. Under the partnership, Signatera will be used to monitor circulating tumor DNA (ctDNA) over multiple timepoints.

While immunotherapies have improved outcomes for patients with advanced melanoma, a substantial proportion of patients fail to respond or later develop treatment resistance. The collaboration targets this unmet need in refractory melanoma. In addition, evaluating treatment response through imaging can be difficult in patients receiving immunotherapy. As a result, longitudinal monitoring of ctDNA may offer earlier and more precise insights into molecular response and disease progression during treatment.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the minimal residual disease (MRD) testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.

Factors like the demand for highly sensitive technologies like next-generation sequencing (NGS) and digital PCR (dPCR), which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.

Other NewsNatera recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in patients with muscle-invasive bladder cancer (MIBC). The approval marks the first companion diagnostic approval in the blood-based minimal residual disease (MRD) testing space and represents a major milestone in personalized oncology care.

NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .

West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.

West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Biodesix, currently carrying a Zacks Rank of 2 (Buy), reported a first-quarter 2026 adjusted loss per share of 81 cents, which came narrower than the Zacks Consensus Estimate by 35.7%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.

BDSX has an estimated earnings growth rate of 36% for 2026. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.5%.

Your personal portfolio doesn't necessarily need to mirror a billionaire investor's holdings. But let's face it -- they manage billion-dollar portfolios for a reason.

And that's what makes Stanley Druckenmiller's current positions so interesting to investors on the hunt for a new pick. The former hedge fund manager doesn't own the obvious and usual suspects, such as Nvidia or Alphabet, even though these names are currently the world's biggest and most ownable publicly traded companies. Rather, Druckenmiller's family's top holding right now is its $600 million position -- 18% of the portfolio -- in a healthcare company called Natera (NTRA 1.86%).

Here's a closer look.

Image source: Getty Images.

What's Natera? With a market cap of just over $30 billion, Natera is not exactly a household name. But Druckenmiller seems to think it could eventually become one. And for good reason.

Natera offers a wide range of genetic testing, including prenatal testing for potential birthing-related problems to determining how a tumor is likely to respond to a particular cancer treatment to figuring out the likelihood that a patient's body will reject a transplanted organ. This information would have been difficult, if not impossible, to know before medical science was able to study DNA in detail.

Natera has taken this young science and made great strides in putting it to marketable use. Last year's top line of $2.3 billion was up 35% year over year. Analysts are looking for revenue of $2.8 billion this year, en route to $3.3 billion next year.

This is still just the beginning, though. An outlook from industry research outfit Precedence Research suggests the worldwide genetic testing business is set to grow at an average annual pace of more than 11% through 2035, when it could be worth more than $70 billion per year. Natera is well-positioned to capture more than its fair share of this growth.

Today's Change

(

-1.86

%) $

-4.07

Current Price

$

215.16

The kicker: While not yet profitable, the company's moving in this direction. The analyst community expects this year's per-share loss of $1.58 to shrink to $0.32 per share next year, before swinging to a profit of $1.43 per share in fiscal 2028.

Given all of this, it's not difficult to see why Druckenmiller is willing to take such a sizable swing on this stock.

Just understand the risk Granted, Druckenmiller can afford to take such a risk, just as he can afford to be patient if the stock underperforms for a while -- a luxury that most ordinary investors simply don't have. That's why you might want to think carefully before following his lead into this name.

You should also know that analysts' earnings forecasts are all over the proverbial map. While the consensus calls for a swing to a per-share profit of $1.43 in 2028, the underlying numbers range from a loss of $1.32 to a profit of $5.03.(Read between the lines: Nobody really knows exactly how well this company is going to grow its top and bottom lines between now and then.)

Still, Druckenmiller has found a name that, at the very least, is worth considering for a small place in your portfolio.

James Brumley has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet, Natera, and Nvidia. The Motley Fool has a disclosure policy.

Key Takeaways NTRA will analyze CLOVER Phase 2 samples to track ctDNA dynamics for CytoDyn's mCRC program.Natera will use Signatera to gauge ctDNA changes and molecular responses linked to leronlimab.NTRA's oncology database ties 2M plasma timepoints to clinical and imaging records for analyses. Natera (NTRA - Free Report) recently announced a collaboration with CytoDyn to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular data in support of the latter’s metastatic colorectal cancer (mCRC) program. The collaboration aims to gain deeper insight into treatment response and disease progression, strengthening the clinical development of leronlimab, CytoDyn’s investigational CCR5-targeting antibody.

Under the collaboration, Natera will analyze clinical samples from CytoDyn’s CLOVER Phase 2 trial, which is evaluating leronlimab in patients with mCRC. Using its Signatera personalized molecular residual disease test, Natera will assess ctDNA changes and molecular response patterns associated with leronlimab treatment.

Management stated that the company is pleased to collaborate with CytoDyn and leverage its extensive real-world molecular oncology database to generate meaningful insights. Natera’s platform helps biopharmaceutical companies to better understand disease biology, treatment response and patient outcomes, supporting informed decision-making across various stages of drug development.

Likely Trend of NTRA Stock Following the NewsShares of NTRA have gained 4.4% since the announcement on Thursday. In the year-to-date period, shares of the company have fallen 6% compared with the industry’s 8.1% decline. However, the S&P 500 has risen 8.1% in the same timeframe.

The agreement expands the application of Natera’s Signatera in clinical-stage oncology programs. The partnership highlights the growing importance of Natera’s oncology database, which combines molecular testing data with clinical and imaging records to generate actionable insights. In the long run, the collaboration strengthens Natera’s position in precision oncology and biopharma research.

NTRA currently has a market capitalization of $30.84 billion.

Image Source: Zacks Investment Research

More on the NewsNatera will provide customized real-world data analyses using its oncology database, which combines more than two million plasma timepoints with clinical and imaging records. By combining molecular response data from Signatera with electronic medical records, the platform can generate insights into treatment response, disease progression and patient outcomes, supporting future clinical development and biomarker-driven strategies for leronlimab.

The collaboration follows the completion of patient enrollment in the CLOVER study, which is investigating leronlimab in combination with trifluridine/tipiracil (TAS-102) and bevacizumab for previously treated mCRC patients. The partnership is expected to complement ongoing biomarker and translational research from the study to further characterize treatment response and guide future development plans.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the minimal residual disease testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.

Factors like the demand for highly sensitive technologies like next-generation sequencing and digital PCR, which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.

Other NewsNatera recently announced a collaboration with Diakonos Oncology to incorporate its Signatera molecular residual disease test into Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial for patients with refractory melanoma.

In May, Natera announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab immunotherapy in patients with muscle-invasive bladder cancer. The approval marks the first companion diagnostic approval in the blood-based minimal residual disease testing space and represents a major milestone in personalized oncology care.

NTRA’s Zacks Rank & Key PicksNatera currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .

West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.

West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Biodesix, currently carrying a Zacks Rank of 2 (Buy), reported a first-quarter 2026 adjusted loss per share of 81 cents, which came narrower than the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.

BDSX has an estimated earnings growth rate of 36% for 2026. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.5%.